RELEVANCE. A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOM. GELA /Grupos cooperativos europeos.
Investigador Principal | Dr. Armando López Guillermo ([email protected]) |
Estado del Protocolo | Cerrado |
Fecha prevista de inicio | |
ULTIMO NEWSLETTER |
DESCARGAR PROTOCOLO |